TITLE

UPDATE ON TREATMENT OF TYPE 2 DIABETES MELLITUS

AUTHOR(S)
RUNGBY, JORGEN
PUB. DATE
January 2017
SOURCE
Problemy Endokrinologii;2017 Supplement, p6
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Type 2 diabetes is a heterogeneous disease and therefore it may be complicated to treat hyperglycaemia. Treatment is ideally based on pathophysiological knowledge about the causes of hyperglycaemia in the individual patient: «The right pill in the right mouth». The lecture will focus on anti-hyperglycaemic treatment, including an introduction to recently introduced drugs and a discussion of recently published outcome trials.
ACCESSION #
124149721

 

Related Articles

  • Antihyperglycaemics: prescribing rate unchanged by rosiglitazone warning.  // Reactions Weekly;12/12/2009, Issue 1282, p5 

    The article discusses research being done on overall utilisation of antihyperglycaemics in the U.S. Military Health System. It references the study "Temporal Trends in Anti-Diabetes Drug Use in Tricare Following Safety Warnings in 2007 About Rosiglitazone," by K. A. Stewart, published in the...

  • The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class? Godinho, Ricardo; Mega, Cristina; Teixeira-de-Lemos, Edite; Carvalho, Eugénia; Teixeira, Frederico; Fernandes, Rosa; Reis, Flávio // Journal of Diabetes Research;5/17/2015, Vol. 2015, p1 

    Incretin-based therapies, the most recent therapeutic options for type 2 diabetes mellitus (T2DM) management, can modify various elements of the disease, including hypersecretion of glucagon, abnormal gastric emptying, postprandial hyperglycaemia, and, possibly, pancreatic β cell dysfunction....

  • Dapagliflozin maintains HR-QOL in diabetes.  // PharmacoEconomics & Outcomes News;10/27/2012, Issue 665, p10 

    The article reports on an international, double-blind clinical trial on the impact of dapagliflozin in health-related quality of life (HR-QOL) of patients with type 2 diabetes.

  • New oral therapies for type 2 diabetes. Purnell, Jonathan Q.; Hirsch, Irl B. // American Family Physician;11/1/1997, Vol. 56 Issue 7, p1835 

    Provides information on several oral agents for the treatment of type two diabetes available in the United States. Side effects of metformin, acarbose, troglitazone; Its mechanism of action of the drugs; Adverse effects of the drugs.

  • Evidence for the Gut Microbiota Short-Chain Fatty Acids as Key Pathophysiological Molecules Improving Diabetes. Puddu, Alessandra; Sanguineti, Roberta; Montecucco, Fabrizio; Viviani, Giorgio Luciano // Mediators of Inflammation;2014, Vol. 2014, p1 

    In type 2 diabetes, hyperglycemia, insulin resistance, increased inflammation, and oxidative stress were shown to be associated with the progressive deterioration of beta-cell function and mass. Short-chain fatty acids (SCFAs) are organic fatty acids produced in the distal gut by bacterial...

  • Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Karalliedde, Janaka; Buckingham, Robin E. // Drug Safety;2007, Vol. 30 Issue 9, p741 

    Thiazolidinediones (TZDs) or glitazones are agents that are widely used for the treatment of type 2 diabetes mellitus. These drugs have a multitude of therapeutic effects including reduction in insulin resistance and hyperglycaemia, anti-inflammatory effects and amelioration of hypertension,...

  • The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus. Brice, Kira R.; Tzefos, Maria K. // Clinical Medicine Insights: Endocrinology & Diabetes;2011, Issue 4, p13 

    Objective: To review the efficacy and safety of glucagon-like peptide-1 (GLP-1) agonists to determine their role in type 2 diabetes mellitus (T2DM). Data sources: A Medline search was conducted using the keywords exenatide, liraglutide, glucagon-like peptide-1, type 2 diabetes mellitus,...

  • Exenatide looks attractive in the UK setting.  // PharmacoEconomics & Outcomes News;6/2/2007, Issue 529, p5 

    The article discusses research being done on exenatide. It references a study by J. A. Ray et al published in the March 2007 issue of "Current Medical Research and Opinion." According to researchers, compared with insulin glargine, exenatide seems likely to represent good value for money for the...

  • Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary care-based analysis. Sharplin, Peter; Gordon, Jason; Peters, John R.; Tetlow, Anthony P.; Longman, Andrea J.; McEwan, Philip // Cardiovascular Diabetology;2009, Vol. 8, p1 

    Background: Insulin glargine (glargine) and premixed insulins (premix) are alternative insulin treatments. This analysis evaluated glycaemic control in 528 patients with type 1 (n = 183) or type 2 (n = 345) diabetes, after switching from premix to a glargine-based regimen, using unselected...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics